Blue-Light Therapy for Seasonal and Non-Seasonal Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors:
Open Access
- 6 May 2022
- journal article
- review article
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 67 (10) , 745-754
Abstract
Objectives: To determine the efficacy and safety of blue-light therapy in seasonal and non-seasonal major depressive disorder (MDD), by comparison to active and inactive control conditions. Methods: We searched Web of Science, EMBASE, Medline, PsycInfo, and Clinicaltrials.gov through January 17, 2022, for randomized controlled trials (RCTs) using search terms for blue/blue-enhanced, light therapy, and depression/seasonal affective disorder. Two independent reviewers extracted data. The primary outcome was the difference in endpoint scores on the Structured Interview Guide for the Hamilton Depression Rating Scale - Seasonal Affective Disorder (SIGH-SAD) or the Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS) between blue light and comparison conditions. Secondary outcomes were response (≥ 50% improvement from baseline to endpoint on a depression scale) and remission rates (endpoint score in the remission range). Results: Of 582 articles retrieved, we included nine RCTs ( n = 347 participants) assessing blue-light therapy. Seven studies had participants with seasonal MDD and two studies included participants with non-seasonal MDD. Four studies compared blue light to an inactive light condition (efficacy studies), and five studies compared it to an active condition (comparison studies). For the primary outcome, a meta-analysis with random-effects models found no evidence for the efficacy of blue-light conditions compared to inactive conditions (mean difference [MD] = 2.43; 95% confidence interval [CI], −1.28 to 6.14, P = 0.20); however, blue-light also showed no differences compared to active conditions (MD = −0.11; 95% CI, −2.38 to 2.16, P = 0.93). There were no significant differences in response and remission rates between blue-light conditions and inactive or active light conditions. Blue-light therapy was overall well-tolerated. Conclusions: The efficacy of blue-light therapy in the treatment of seasonal and non-seasonal MDD remains unproven. Future trials should be of longer duration, include larger sample sizes, and attempt to better standardize the parameters of light therapy.Keywords
Funding Information
- Michael Smith Health Research BC (18925)
This publication has 39 references indexed in Scilit:
- Bright-Light Therapy in the Treatment of Mood DisordersNeuropsychobiology, 2011
- Low-intensity blue-enriched white light (750 lux) and standard bright light (10 000 lux) are equally effective in treating SAD. A randomized controlled studyBMC Psychiatry, 2011
- Spectral quality of light modulates emotional brain responses in humansProceedings of the National Academy of Sciences, 2010
- Narrow-band blue-light treatment of seasonal affective disorder in adults and the influence of additional nonseasonal symptomsDepression and Anxiety, 2009
- A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD)BMC Psychiatry, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Effects of different wavelengths in seasonal affective disorderJournal of Affective Disorders, 1990
- The file drawer problem and tolerance for null results.Psychological Bulletin, 1979
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960